Antibiotic resistance and antibiotic development

The Lancet Infectious Diseases

Volumn 8, Issue 4, 2008, Pages 211-212

  Spellberg, Brad ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EUROPE; FOOD AND DRUG ADMINISTRATION; INFECTION; LETTER; MULTIDRUG RESISTANCE; PATENT; PRIORITY JOURNAL; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG EVALUATION; DRUG RESISTANCE, BACTERIAL; HUMANS; RESEARCH;

EID: 40749160489     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70048-3     Document Type: Letter

References (15)

1. Outterson K., Samora J., and Keller-Cuda K. Will longer antimicrobial patents improve global public health?. Lancet Infect Dis 7 (2007) 559-566
2. Bradley J., Guidos R., Baragona S., et al. Anti-infective research and development-problems, challenges, and solutions. Lancet Infect Dis 7 (2007) 68-78
3. Spellberg B., Powers J., Brass E., Miller L., and Edwards J. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38 (2004) 1279-1286
4. Talbot G., Bradley J., Edwards J., et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
5. CDC. Antimicrobial resistance: a growing threat to public health (2002), Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA
6. Palumbi S. Humans as the world's greatest evolutionary force. Science 293 (2001) 1786-1790
7. Alanis A. Resistance to antibiotics: are we in the post-antibiotic era?. Arch Med Res 36 (2005) 697-705
8. IDSA. Bad bugs, no drugs: as antibiotic discovery stagnates...a public health crisis brews (2004), Infectious Diseases Society of America, Alexandria, VA. http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554 (accessed Feb 19, 2008).
9. Spellberg B., Miller L., Kuo M., Bradley J., Scheld W., and Edwards J. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development. Infection 35 (2007) 167-174
10. Generic Pharmaceutical Association. Legislation promoted as a countermeasure against bioterrorism would counter bipartisan measures to constrain prescription costs (2006), Generic Pharmaceutical Association, Arlington, VA
11. Burrill & Company. Biopharmaceutical industry research & development tops $55 billion in 2006 (2007), Burrill & Company, San Francisco. http://www.burrillandco.com/burrill/pr_1171302475 (accessed Feb 19, 2008).
12. National Institutes of Health. Summary of the FY 2007 President's budget (2007), National Institutes of Health, Bethesda, MD. http://officeofbudget.od.nih.gov/pdf/Press%20info%20final.pdf (accessed Feb 25, 2008).
13. DiMassa J., Hansen R., and Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ 22 (2003) 151-185
14. Leaf C. Why we're losing the war on cancer. Fortune Magazine (March 22, 2004). http://money.cnn.com/magazines/fortune/fortune_archive/2004/03/22/365076/index.htm (accessed Feb 25, 2008).
15. FDA. Electronic orange book query. Rockville, MD: US Food and Drug Administration. http://www.fda.gov/cder/ob/ (accessed Jan 7, 2008).